Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RET alterations are key drivers in multiple human cancers.
• Resistance mutations to current RET inhibitors limit therapeutic efficacy.
• Novel inhibitors are needed to overcome resistance and improve treatment outcomes.

Purpose of the Study:

• To characterize CN-3, a novel RET inhibitor.
• To evaluate CN-3's activity against clinically relevant RET mutants.
• To assess CN-3's preclinical efficacy and tolerability in RET-driven cancers.

Main Methods:

• In vitro kinase assays to determine IC50 values against RET mutants.
• Cell proliferation assays in RET-driven cancer cell lines and Ba/F3 models.
• Western blotting to analyze downstream signaling pathways (SHC/AKT/ERK).
• In vivo xenograft studies in mouse models.
• Kinase profiling for off-target activity assessment.

Main Results:

• CN-3 potently inhibited all tested RET mutants (IC50 < 5 nM).
• CN-3 selectively suppressed proliferation in RET-driven cellular models and Ba/F3 cells.
• CN-3 blocked RET autophosphorylation and downstream signaling, inducing cell cycle arrest and apoptosis.
• CN-3 demonstrated dose-dependent antitumor efficacy and good tolerability in xenografts.
• Kinase profiling showed moderate selectivity, with limited off-target effects.

Conclusions:

• CN-3 is a potent RET inhibitor active against clinically relevant RET mutants.
• CN-3 exhibits selective anti-proliferative effects and induces cell death in RET-driven cancer models.
• CN-3 shows promising preclinical antitumor efficacy and tolerability.
• CN-3 represents a potential lead candidate for next-generation RET-targeted cancer therapies.